Free Trial
NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Bolt Biotherapeutics logo
$4.84 0.00 (0.00%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$4.83 -0.01 (-0.21%)
As of 09/4/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Key Stats

Today's Range
$4.84
$4.95
50-Day Range
$4.84
$6.71
52-Week Range
$4.59
$14.36
Volume
2,938 shs
Average Volume
14,239 shs
Market Capitalization
$9.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.50
Consensus Rating
Hold

Company Overview

Bolt Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

BOLT MarketRank™: 

Bolt Biotherapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bolt Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.61) to ($1.12) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bolt Biotherapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bolt Biotherapeutics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bolt Biotherapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bolt Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.79% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bolt Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Bolt Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.79% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 6.10% of the stock of Bolt Biotherapeutics is held by insiders.

    • Percentage Held by Institutions

      86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Bolt Biotherapeutics' insider trading history.
    Receive BOLT Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    BOLT Stock News Headlines

    Retire Comfortably with These New Monthly Income ETFs?
    Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.tc pixel
    See More Headlines

    BOLT Stock Analysis - Frequently Asked Questions

    Bolt Biotherapeutics' stock was trading at $10.7020 at the beginning of 2025. Since then, BOLT stock has decreased by 54.8% and is now trading at $4.84.

    Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings results on Thursday, August, 14th. The company reported ($4.46) EPS for the quarter, beating the consensus estimate of ($6.40) by $1.94. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.82 million.

    Shares of Bolt Biotherapeutics reverse split before market open on Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Bolt Biotherapeutics (BOLT) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

    Top institutional shareholders of Bolt Biotherapeutics include Vivo Capital LLC (9.17%), Sofinnova Investments Inc. (7.17%), Nan Fung Group Holdings Ltd (3.04%) and Board of Trustees of The Leland Stanford Junior University (1.87%). Insiders that own company stock include Edgar Engleman, Vivo Capital Viii, Llc, William P Quinn and Sarah Nemec.
    View institutional ownership trends
    .

    Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV).

    Company Calendar

    Last Earnings
    8/14/2025
    Today
    9/04/2025
    Next Earnings (Estimated)
    11/11/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Biotechnology
    Current Symbol
    NASDAQ:BOLT
    CIK
    354655
    Fax
    N/A
    Employees
    90
    Year Founded
    2015

    Price Target and Rating

    High Price Target
    $75.00
    Low Price Target
    $20.00
    Potential Upside/Downside
    +881.4%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.33
    Research Coverage
    3 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($26.66)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$63.12 million
    Net Margins
    N/A
    Pretax Margin
    -1,217.02%
    Return on Equity
    -91.67%
    Return on Assets
    -53.19%

    Debt

    Debt-to-Equity Ratio
    0.56
    Current Ratio
    3.11
    Quick Ratio
    3.11

    Sales & Book Value

    Annual Sales
    $7.69 million
    Price / Sales
    1.21
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $20.24 per share
    Price / Book
    0.24

    Miscellaneous

    Outstanding Shares
    1,920,000
    Free Float
    1,326,000
    Market Cap
    $9.29 million
    Optionable
    Not Optionable
    Beta
    0.90

    Social Links

    A Guide To High-Short-Interest Stocks Cover

    MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

    Get This Free Report

    This page (NASDAQ:BOLT) was last updated on 9/5/2025 by MarketBeat.com Staff
    From Our Partners